Company Overview
| Stock Name | Modern Chi Med |
|---|---|
| Stock Code | 01643 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 主要從事生產中成藥,提供中老年人士使用的非處方藥及處方藥,擁有59種中成藥產品,主要產品包括補腎填精丸、氣血雙補丸、山玫膠囊、金匱腎氣丸、心安膠囊、加味逍遙丸、護肝片、加味藿香正氣丸及清瘟解毒丸。 |
| Listing Date | 2021-01-15 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 河北省承德市津圍公路88號 |
| Business Address (Hong Kong) | 香港 皇后大道東183號 合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | cdysjdyy.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 1.18 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 3,000 shares |
| Entry Threshold | HK$ 3,540 |
| Par Value | RMB 0.01 / shares |
| Offer Period | 2020-12-31 to 2021-01-07 |
| Global Offering Shares | 150,000,000 shares |
| HK Public Offer Shares (Initial) | 15,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | 5,000lots (Pool A2,500lots,Pool B2,500lots) |
| International Placing Shares (Initial) | 135,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 600,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 177,000,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 3,000 | HK$ 3,540 |
| 2 lots | 6,000 | HK$ 7,080 |
| 3 lots | 9,000 | HK$ 10,620 |
| 4 lots | 12,000 | HK$ 14,160 |
| 5 lots | 15,000 | HK$ 17,700 |
| 6 lots | 18,000 | HK$ 21,240 |
| 7 lots | 21,000 | HK$ 24,780 |
| 8 lots | 24,000 | HK$ 28,320 |
| 9 lots | 27,000 | HK$ 31,860 |
| 10 lots | 30,000 | HK$ 35,400 |
| 15 lots | 45,000 | HK$ 53,100 |
| 20 lots | 60,000 | HK$ 70,800 |
| 25 lots | 75,000 | HK$ 88,500 |
| 30 lots | 90,000 | HK$ 106,200 |
| 35 lots | 105,000 | HK$ 123,900 |
| 40 lots | 120,000 | HK$ 141,600 |
| 45 lots | 135,000 | HK$ 159,300 |
| 50 lots | 150,000 | HK$ 177,000 |
| 100 lots | 300,000 | HK$ 354,000 |
| 150 lots | 450,000 | HK$ 531,000 |
| 200 lots | 600,000 | HK$ 708,000 |
| 250 lots | 750,000 | HK$ 885,000 |
| 300 lots | 900,000 | HK$ 1,062,000 |
| 350 lots | 1,050,000 | HK$ 1,239,000 |
| 400 lots | 1,200,000 | HK$ 1,416,000 |
| 450 lots | 1,350,000 | HK$ 1,593,000 |
| 500 lots | 1,500,000 | HK$ 1,770,000 |
| 750 lots | 2,250,000 | HK$ 2,655,000 |
| 1,000 lots | 3,000,000 | HK$ 3,540,000 |
| 1,250 lots | 3,750,000 | HK$ 4,425,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,500 lots | 4,500,000 | HK$ 5,310,000 |
| 1,750 lots | 5,250,000 | HK$ 6,195,000 |
| 2,250 lots | 6,750,000 | HK$ 7,965,000 |
| 2,500 lots | 7,500,000 | HK$ 8,850,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 833.4M |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +1066% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 708,000,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣46.2百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 60,000,000 |
| Listing Expenses / Funds Raised | ~33.9% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2017 | 2018 | 2019 |
|---|---|---|---|
| Revenue | 106,466 | 173,512 | 218,767 |
| Cost of sales | -62,039 | -99,855 | -119,698 |
| Gross profit | 44,427 | 73,657 | 99,069 |
| Other income and gains, net | 452 | 770 | 174 |
| Selling and distribution expenses | -4,270 | -4,938 | -8,105 |
| Administrative expenses | -4,648 | -4,982 | -14,124 |
| Operating profit | 35,961 | 64,507 | 65,256 |
| Net finance costs | -1,191 | 0 | 0 |
| Profit before tax | 34,770 | 64,507 | 65,256 |
| Income tax expense | -8,889 | -16,270 | -19,019 |
| Profit for the year | 25,881 | 48,237 | 46,237 |
Balance Sheet
| Item | 2017 | 2018 | 2019 | 2020-09 |
|---|---|---|---|---|
| Cash and cash equivalents | 12,865 | 89,940 | 35,891 | |
| Trade and bills receivables | 32,857 | 28,680 | 27,737 | |
| Inventories | 53,553 | 39,011 | 40,933 | |
| Total current assets | 99,275 | 157,631 | 104,561 | |
| Total assets | 116,243 | 173,014 | 123,110 | |
| Total current liabilities | 40,661 | 49,195 | 54,256 | |
| Total liabilities | 40,661 | 49,195 | 54,256 | |
| Total equity | 75,582 | 123,819 | 68,854 | |
| Equity attributable to owners | 75,582 | 123,819 | 68,854 | |
| Interest-bearing borrowings | 0 | 0 | 5,000 | 5,000 |
Cash Flow Statement
| Item | 2017 | 2018 | 2019 | 2020-09 |
|---|---|---|---|---|
| Net cash from operating activities | -25,455 | 77,112 | 40,240 | |
| Net cash from investing activities | -1,542 | -37 | -1,207 | |
| Net cash from financing activities | -41,989 | 0 | -92,943 | |
| Net increase in cash | -68,986 | 77,075 | -53,910 | |
| Depreciation of PP&E | 1,802 | 1,716 | 1,550 | 1,343 |
| Purchase of PP&E | -1,933 | -172 | -2,619 | -446 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 1.26 |
|---|---|
| First Day Open | HK$ 1.17 |
| First Day Change | 6.78% |
| First Day Volume | 83169000.0 |
| First Day Turnover | 103949000.0 |
| Use of Proceeds | 1、約44.0%或51.7百萬港元將用于提高及擴大產能,進一步生產我們的主要膠囊處方藥;
2、約16.8%或19.7百萬港元將用于擴大我們華南及華東的分銷網絡;
3、約10.2%或12.0百萬港元將用于提高品牌知名度,方法為媒體營銷及推廣;
4、約19.9%或23.4百萬港元將用于進一步加大研發力度、采購質量管理設備及 擴大產品組合,長遠而言為業務增值;
5、約3.4%或4.0百萬港元將用于升級IT系統;
6、約5.7%或6.6百萬港元將撥作營運資金及用作其他一般公司用途。 |
Underwriting Syndicate
Sole Sponsor (1)
Soochow Securities International Capital Limited CE BBG379
Joint Bookrunners (8)
东吴证券国际经纪有限公司 CE AYA587
CS Wealth Securities Limited CE AAD244
SPDB International Capital Limited CE BFZ375
交银国际证券有限公司 CE APJ121
YUE XIU SECURITIES COMPANY LIMITED CE ABQ722
SHANXI SECURITIES INTERNATIONAL LIMITED CE BEM330
SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927
Apricot Capital (Hong Kong) Limited CE ACX624
Joint Lead Managers (13)
东吴证券国际经纪有限公司 CE AYA587
CS Wealth Securities Limited CE AAD244
SPDB International Capital Limited CE BFZ375
交银国际证券有限公司 CE APJ121
YUE XIU SECURITIES COMPANY LIMITED CE ABQ722
SHANXI SECURITIES INTERNATIONAL LIMITED CE BEM330
SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927
Apricot Capital (Hong Kong) Limited CE ACX624
ZMF Asset Management Limited CE AWF641
DL SECURITIES (HK) LIMITED CE AZN279
FORTHRIGHT SECURITIES COMPANY LIMITED CE BGP713
CNI Securities Group Limited CE ATM582
MASTERLINK SECURITIES (HONG KONG) CORPORATION LIMITED CE ACS304
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 謝偉 | — |
| Company Secretary | 劉靜詩 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 現代生物科技(由謝先生全資擁有)持有450,000,000股股份,佔緊隨全球發售及資本化發行完成後已發行股本約75%,謝先生被視為持有同等權益。 |
|---|




